1. Home
  2. Directory
  3. Texas
  4. Houston
  5. Nurse Practitioner
  6. NPI Profile
  7. Prescriptions 1669615365

MRS. CONNIE LACOUR HUGHES NP
Prescription History 1669615365
Nurse Practitioner - Adult Health in Houston, TX

NPI Status: Active since April 09, 2009

Contact Information

15655 CYPRESS WOOD MEDICAL DR STE 100
HOUSTON, TX
ZIP 77014
Phone: (713) 442-1700

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MRS. CONNIE LACOUR HUGHES NP, an active Adult Health specialist practicing in Houston, TX. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 197 documented patient claims. Among these therapy options, the most frequently utilized medication is Eliquis, which accounts for 95 claims alone.

Medication Index

A
E
H
X
No matching medications currently found on file.

Alendronate Sodium

Generic Formulation: Alendronate SodiumSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 14
30-Day Fills 37.4
Days Supply 1,120
TX State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills118.8
Peer Average Days Supply3,535
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 71.4% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $171.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.26

State Avg Cost Per Claim

$13.01

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

Therapeutic Applications

Alendronate is used to prevent and treat certain types of bone loss (osteoporosis) in adults. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases as you age, after menopause, or if you are taking corticosteroid medications (such as prednisone) for a long time. This medication works by slowing bone loss. This effect helps maintain strong bones and reduce the risk of broken bones (fractures). Alendronate belongs to a class of drugs called bisphosphonates.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 32
30-Day Fills 94.0
Days Supply 2,820
TX State Average Benchmarks
Peer Average Claims65.0
Peer Average 30-Day Fills155.7
Peer Average Days Supply4,650
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 50.8% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $552.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.28

State Avg Cost Per Claim

$24.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Eliquis

Generic Formulation: ApixabanSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 95
30-Day Fills 131.5
Days Supply 3,905
TX State Average Benchmarks
Peer Average Claims76.0
Peer Average 30-Day Fills120.8
Peer Average Days Supply3,403
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $73,239.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$770.94

State Avg Cost Per Claim

$810.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 35
30-Day Fills 96.7
Days Supply 2,900
TX State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills64.6
Peer Average Days Supply1,915
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,164.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.28

State Avg Cost Per Claim

$38.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Xarelto

Generic Formulation: RivaroxabanSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 21
30-Day Fills 35.0
Days Supply 1,050
TX State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills81.8
Peer Average Days Supply2,343
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 54.3% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $18,952.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$902.49

State Avg Cost Per Claim

$903.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MRS. CONNIE LACOUR HUGHES NP provides transparency into local medical care patterns within Houston, TX.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Adult Health** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.